Bristol-Myers Squibb Award Goes to Folkman

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

NEW YORK--Judah Folkman, MD, who first theorized that tumors form and metastasize by means of angiogenesis, is the winner of the 18th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.

NEW YORK--Judah Folkman, MD, who first theorized that tumors formand metastasize by means of angiogenesis, is the winner of the18th annual Bristol-Myers Squibb Award for Distinguished Achievementin Cancer Research.

In 1971, Dr. Folkman reported the isolation of the first angiogenicfactor, a substance that induces blood vessel growth. In 1984,he and his colleagues Yuen Shing and Michael Klagsbrun purifiedthe first tumor-derived angiogenic factor, and Dr. Folkman laterdiscovered the first angiogenesis inhibitor.

Dr. Folkman is Julia Dyckman Andrus Professor of Pediatric Surgery,Harvard Medical School, and director of the Surgical ResearchLaboratory, Children's Hospital, Boston.

The company also announced the recipients of the 1995 Bristol-MyersSquibb Unrestricted Cancer Research Grants--Indiana UniversityCancer Center and the National Cancer Institute, Milan.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.